

ASX ANNOUNCEMENT

Tuesday, 19 August 2025

Planned Retirement of the Chief Financial Officer

IDT Australia Limited (ASX: IDT) (IDT or the Company) wishes to announce the planned retirement of its Chief Financial Officer (CFO), Mahendran Vasanthakumar, at the end of this month following a career spanning over four decades in finance and accounting.

IDT's Executive Chair, Mark Simari, said:

"On behalf of the Board and the team at IDT, I would like to extend our gratitude to Vasantha for his invaluable contribution to our Company. He joined IDT at a crucial time when we were undertaking our strategic pivot and delayed his retirement until IDT completed the first phase of its transformation. We wish him the very best for the future."

IDT is taking this opportunity to restructure its finance department and has appointed Mr. Malika Perera as Head of Finance. He has more than two decades of senior financial, commercial and operational leadership experience across pharmaceuticals, manufacturing and distribution sectors.

Malika holds an MBA from the University of Southern Queensland, is a CPA Australia member, an Associate of the Chartered Institute of Management Accountants (UK), a Chartered Global Management Accountant (AICPA/CIMA), and an Associate of the Chartered Institute of Marketing (UK). He also holds a First-Class Honours Degree in Computer Science and is a professional member of the Chartered Institute for IT (UK).

Ends..../

Authorised by the Board of Directors of IDT Australia Limited.

For investor and media enquiries, please contact:

Brendon Lau

E: brendon@vantagepointpartners.com.au

M: +61 409 341 613

About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.



Forward-looking statements

This announcement contains or may contain forward-looking statements that are based on IDT Australia's beliefs, assumptions, and expectations and on information currently available to IDT Australia.

All statements that address operating performance, events, or developments that IDT Australia or its directors expect or anticipate will occur in the future are forward-looking statements, including, without limitation, statements as to the expectations of IDT Australia or the market it operates in.

IDT Australia believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. IDT Australia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. No assurance or guarantee is, or should be taken to be, given in relation to, and no reliance should be placed on, the future business performance or results of IDT Australia or the likelihood that the current assumptions, estimates or outcomes will be achieved. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.